Opioid analgesic controlled-release - Akela Pharma

Drug Profile

Opioid analgesic controlled-release - Akela Pharma

Alternative Names: EDACS™-based opioid analgesic

Latest Information Update: 18 Mar 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Akela Pharma
  • Class Opiate alkaloids
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 14 Mar 2013 Akela Pharma and its subsidiaries cease operations
  • 14 Mar 2013 Discontinued - Phase-I for Pain in Canada (PO)
  • 06 Mar 2008 Phase-I clinical trials in Pain in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top